The Estée Lauder Companies Inc. (EL) Q4 2025 Earnings Call Transcript

Estée Lauder reported an 8% organic sales decline for fiscal 2025, largely driven by a 28% drop in travel retail, which now represents 15% of sales. Despite this, gross margin expanded 230 basis points to 74% due to its Profit Recovery and Growth Plan (PRGP), though operating margin contracted to 8% amid increased consumer-facing investments and sales deleverage, alongside $425 million in impairment charges. For fiscal 2026, the company projects a return to low single-digit organic sales growth (flat to +3%), anticipating mid-single-digit growth in Mainland China and a recovery in travel retail, while expanding operating margin by 165 basis points to 9.4-9.9% and diluted EPS by 26-39%. This outlook, supported by ongoing PRGP benefits, strategic shifts like expanded online presence, and organizational restructuring, signals the start of a turnaround aiming for sustainable growth and double-digit operating margins in the years ahead.

Analysis

Estée Lauder's fiscal 2025 results reflect a company in a deep, deliberate transition, marked by a headline 8% organic sales decline and a 42% drop in diluted EPS. The primary driver of the sales contraction was a strategic 28% reduction in the travel retail channel, which has successfully lowered the channel's contribution to 15% of total sales, de-risking exposure to its volatility. Despite significant volume deleverage, the company demonstrated strong cost management, expanding gross margin by 230 basis points to 74% through its Profit Recovery and Growth Plan (PRGP). However, operating margin contracted to 8%, pressured by the sales decline, increased consumer-facing investments, and a notable $425 million impairment charge on the Dr.Jart+ and Too Faced brands, indicating challenges with underperforming past acquisitions.

The forward-looking guidance for fiscal 2026 signals a pivotal turnaround, forecasting a return to low single-digit organic sales growth (flat to +3%) and an operating margin expansion of approximately 165 basis points to a 9.4%-9.9% range. This recovery is predicated on momentum from the 'Beauty Reimagined' strategy, which includes aggressive expansion into online channels like Amazon, a renewed focus on high-growth emerging markets, and an innovation pipeline targeted to represent over 25% of sales. Management's ability to forecast margin expansion while absorbing an estimated $100 million in tariff headwinds and reinvesting in growth underscores confidence in the PRGP's efficacy. A key challenge remains the gap between retail sell-out and net sales, particularly in North America, which the company aims to narrow throughout the year.

Key Decisions for Investors

• The investment thesis now centers on execution of the 'Beauty Reimagined' turnaround; investors should monitor the narrowing of the gap between retail and net sales as a primary indicator of successful inventory and channel management.
• Focus on operating margin expansion as the key performance metric for fiscal 2026, as the company's ability to achieve its 9.4%-9.9% target despite modest sales growth and tariff headwinds will validate the effectiveness of its cost-cutting and restructuring programs.
• Track the progress of channel diversification, particularly the growth and profitability of the Amazon partnership and expansion in emerging markets, as these are critical to offsetting softness in Europe and the reduced, albeit more stable, travel retail business.
• Anticipate strategic portfolio actions, given the engagement of external advisors and the significant impairment charges on Dr.Jart+ and Too Faced, which could lead to divestitures aimed at streamlining operations and focusing on higher-return brands.